| Literature DB >> 30880540 |
Zhouliang Bian1, Yiding Gui1, Fan Feng1, Hongxing Shen1, Lifeng Lao1.
Abstract
BACKGROUND: This study was performed to compare different surgical approaches in the treatment of spinal tuberculosis.Entities:
Keywords: Surgical treatment; blood loss; lumbar tuberculosis; operative time; spinal tuberculosis; surgical approach; thoracic tuberculosis
Mesh:
Year: 2019 PMID: 30880540 PMCID: PMC7581984 DOI: 10.1177/0300060519830827
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Flow diagram for selection of studies and specific reasons for exclusion.
Previous reports of surgical treatment of thoracic and lumbar spinal tuberculosis.
| Authors | Study design | Year, journal | Patients, n | Age, y | Symptom duration, mo | Level of spondylitis | Involved vertebral bodies, n (average) | Fusion level | Chemotherapy | Follow-up, mo | Clinical outcome | Fusion rates |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee et al.[ | Retrospective | 2006 | A: 7P: 10 | A: 49.0P: 63.7 | A: 4.14P: 2.95 | A: T: 3 TL: 4P:T: 6TL: 4 | A: 2.29P: 2.20 | A: 4.14P: 4.40 | preop: at least 2 weeks; postop: INH/RFP/EMB/PYZ: 2 mo, followed by INH/RFP: 10 mo | 18 (6-42) | VAS, CRP: nosignificant difference;Frankel grade: improved in both groups | A & P: 100% |
| Ma et al.[ | Retrospective | 2012 | A: 74P: 83 | A: 38.3P: 39.8 | N/A | A: T: 39TL: 27L: 8P: T: 13TL: 11L: 59 | N/A | A: 4.11P: 4.21 | postop: INH/RFP/EMB/PYZ: 3 mo, followed by INH/RFP/EMB: 9 mo | 37 (22-72) | ESR: P > 0.05Excellent and good: A: 70P: 78P > 0.05 | A & P: 100% |
| Cui et al.[ | Retrospective | 2013 | A: 74P: 70 | N/A | N/A | A:T: 39TL: 27L: 8P:T: 4TL: 7L: 39LS: 20 | A: 2.89P: 2.95 | A: 4.11P: 4.21 | A & P: postop: INH/RFP/EMB/PYZ: 3 mo, followed by INH/RFP/EMB: 9 mo | 37±6.9 | ODI, ESR, ASIA impairment score: improved, no deterioration | A: 92.5%P: 91.6% |
| Qureshi et al.[ | Retrospective | 2013 | A: 57AP: 30 | N/A | N/A | N/A | N/A | N/A | preop: at least 4 weeks; postop: INH/RFP/EMB/PYZ: 3 mo, followed by INH/RFP/EMB: at least 9 mo | 64 (16-132) | Denis scale and ASIA impairment score: improved but no significant difference between A and AP | 100% in each group |
| He and Xu[ | Retrospective | 2012 | A: 13AP: 14 | A: 40.0AP: 36.0 | A: 6.8AP: 7.5 | A: L5: 2S1: 3L5S1: 8AP: L5: 4S1: 1L5S1: 9 | A: 1AP: 1 | N/A | preop: at least 4 weeks; postop: INH/RFP/EMB/PYZ: 12 mo | Average: 25 | VAS, ODI, ASIA impairment score: improved postop, but no significant difference between A and AP | N/A |
| El-Sharkawi and Said[ | Retrospective | 2012 | AP: 25P: 32 | AP: 47.6P: 48.7 | N/A | N/A | AP: 2.16P: 2.12 | N/A | N/A | AP: 6.1±2.2 yrsP: 4.6±1.7yrs | VAS, ASIA impairment score: improved but no significant difference between AP and P | AP&P: 100% |
| Zhang et al.[ | Retrospective | 2012 | AP: 16P: 20 | AP: 68.2 P: 68.6 | N/A | N/A | AP: 2.35P: 2.44 | N/A | preop: 3-5 weeks; postop: INH/RFP/EMB/PYZ: 9 mo, followed by INH/RFP/HRE: 3-6 mo | AP: 34.1±5.7P: 35.8±5.8 | CRP, ESR, Frankel scale: improved but no significant difference between AP and P | N/A |
| Wang et al.[ | Retrospective | 2014 | AP: 55P: 60 | Total: 48.6±12.8 | N/A | AP: T: 15TL: 28L: 12P: T: 18TL: 31L: 11 | N/A | N/A | preop: 2-4 weeks; postop: INH/RFP/EMB/PYZ: 6 mo, followed by INH/RFP/EMB: at least 9-12 mo | 21.3 (12-36) | CRP, ESR, ASIA impairment score: improved but no significant difference between A P and P | N/A |
| Mehta and Bhojraj[ | Retrospective | 2001 | A: 12AP: 16P: 13 | A: 35.3AP: 31.3P: 67 | N/A | N/A | A: 1.75AP: 2.06 | N/A | N/A | A: 29 (7-55)AP: 34 (6-60)P: 35 (6-61) | Frankel grade: improved in each group | N/A |
| Li et al.[ | Retrospective | 2013 | A: 7AP: 18P: 18 | A: 37.7AP: 32.2P: 34.9 | A: 7.0AP: 16.0P: 32.9 | N/A | A: 3.7AP: 4.1P: 5.0 | N/A | postop: INH/RFP/EMB/PYZ: 3 mo, followed by INH/RFP/PYZ: 9-15 mo | 29.6 (18-63) | ESR, ASIA impairment score: improved in each group | 100% for each group |
| Zhang et al.[ | Observational | 2017 | A: 32AP: 42P: 63 | A: 63.2AP: 68.2P: 65.6 | A: 9.2AP: 7.5P: 65.6 | A: L: 32AP: L: 42P: L: 63 | A: 1: 172: 153 or 4: 10AP: 1: 102: 123 or 4: 10P: 1: 262: 303 or 4: 7 | N/A | preop: INH/RFP/EMB/PYZ 4-6 weekspostop: 12-18 mo | A: 83.4±2.4AP: 85.9±4.5P: 82.7±2.8 | VAS, ODI, Macnab excellent/good rate, Frankel grade: improved but no significant difference among 3 groups | N/A |
| Huang et al.[ | Retrospective | 2017 | A: 37P: 149 | A: 46.6P: 50.9 | A: 12.0P: 11.7 | A: L: 19T: 18P: L: 73T: 76 | A: 2.22P: 2.24 | N/A | preop: INH/RFP/EMB/PYZ: 4-6 weekspostop: at least 12 mo | 1 year | Cobb’s angle, VAS pain score, Frankel grade: improved but no statistically significant difference between 2 groups | N/A |
| Liu et al.[ | Retrospective | 2015 | A:T: 10, L: 10AP:T: 10, L: 10P:T: 10, L: 10 | A: 0-20: 021-40: 1441-60: 461-80: 2AP: 0-20: 021-40: 1041-60: 661-80: 4P: 0-20: 121-40: 741-60: 961-80: 3 | N/A | N/A | A: 1.85AP: 2.11P: 2.00 | N/A | INH/RFP/EMB/PYZ at least 4 weeks | Average: 60 | N/A | N/A |
| Cui et al.[ | Retrospective | 2016 | A: 39P: 42 | N/A | N/A | A: 3.30P: 3.95 | A: 2.3±0.5P: 3.2±0.9 | postop: INH/RFP/EMB/PYZ: 3 mo, followed by INH/RFP/EMB: at least 9 mo | 17-72 (average: 37) | VAS, CRP, ESR: nosignificantdifference | N/A | |
| Hassan et al.[ | Retrospective | 2016 | A: 20P: 33 | A: 35.90±10.48P: 35.64±12.07 | N/A | A: T: 10TL: 5L: 5P: T: 12TL: 6L: 4 | N/A | N/A | preop: at least 2 weeks; postop: 9 mo | 12-24 (average: 15) | ASIA, VAS, ODI: improved but no significant difference between A and P | A: 100%P: 95.4% |
| Assaghir et al.[ | Retrospective cohort | 2016 | A: 43P: 49 | A: 49.5±11.2P: 47.0±7.0 | A: 8.7±2.3P: 7.5±2.5 | A: T: 43P: T: 49 | A: 1: 43P: 1: 49 | N/A | preop: INH/RFP/EMB: 3 weeks | A: 48.0±7.9 moP: 47.5±9.5 mo | Frankel classification, ODI: no statistically significant differences between the 2 groups | A: 100%P: 100% |
| Wang et al.[ | Retrospective | 2017 | A: 57AP: 65P: 62 | A: 40.1±13.2AP: 38.5±14.5P: 39.3±15.1 | A: 9.6±4.8AP: 9.8±5.2P: 9.5±4.9 | N/A | N/A | N/A | preop: HRZE for 2-4 weekspostop: anti-TB chemotherapy with HRZE for at least 18 mo | A: 73.6±4.5AP: 74.3±4.2P: 72.7±3.8 | ESR, CRP, ASIA: improved but no statistically significant difference among 3 groups | N/A |
| Liu et al.[ | Retrospective | 2016 | AP: 36P: 22 | AP: 40.5±16.5P: 43.9±12.1 | N/A | AP: L1-2: 15L2-3: 9L3-4: 2L4-5: 9L5-S1: 1P: L1-2: 4L2-3: 4L3-4: 1L4-5: 10L5-S1: 3 | N/A | N/A | preop: at least 2 weeks; postop: INH/RFP/EMB/PYZ: 2 mo, followed by INH/RFP/EMB: for 7-10 mo | AP: 22.3±6.2P: 21.6±5.7 | ESR, CRP, ASIA: improved but no statistically significant difference among 3 groups | AP: 100%P: 100% |
| Omran et al.[ | Retrospective | 2017 | A: 22P: 23 | Total: 32.5±4.5 | N/A | A: T: 12TL: 8L: 2P: T: 13TL: 5L: 5 | N/A | N/A | preop: ATT 1 yearpostop: parenteral cephalosporin until drain removal, INH/RFP/EMB/PYZ for 3 mo, followed by INH/RFP/EMB for at least 9 mo | A: 36±5.5P: 36±5.5 | VAS, ODI, ESR, CRP, ASIA: improved but with no significant difference between the 2 groups | A: 91.3%P: 100% |
| Xu et al.[ | Retrospective case-control | 2015 | AP: 16P: 17 | AP: 69.8±4.2P: 70.5±5.1 | N/A | AP: L: 16P: L: 17 | N/A | N/A | preop: INH/RFP/EMB/PYZ: 2-3 weekspostop: same regimen for 12-18 mo | AP: 41.4±4.2P: 41.3±3.7(average: 41.3) | ESR, VAS, ASIA: improved but no statistically significant difference between 2 groups | AP: 100.00%P: 94.12% |
| Shi et al.[ | Retrospective | 2014 | A: 78AP: 54P: 16 | A: 41.0AP: 37.9P: 39.1 | A: 7.3AP: 7.1P: 8.0 | A: T1-T4: 0T5-T9: 33T10-L2: 31L3-L4: 14L5-S1: 0AP: T1-T4: 4T5-T9: 6T10-L2: 20L3-L4: 7L5-S1: 17P: T1-T4: 0T5-T9: 0T10-L2: 4L3-L4: 11L5-S1: 1 | A: 1.72AP: 1.63P: 1.25 | N/A | N/A | A: >6 mo: 71AP: >6 mo: 53P: >6 mo: 15 | ASIA: only significantly improved in the nails+screws and pedicle screws groupsESR, CRP: improved significantly in all groups | Within 2 weeks A: 91.03%AP: 98.15%P: 83.75% |
| Lin et al.[ | prospective consecutive cohort | 2015 | A: 21P: 22 | A: 39.4±12.8P: 39.0±11.8 | N/A | A: T1: 3T2: 8T3: 6T4: 4P: T1: 2T2: 9T3: 8T4: 3 | N/A | N/A | preop: INH/RFP/EMB/PYZ: 2-4 weekspostop: same regimen for 12-18 mo | N/A | Frankel scale: improved but no statistically significant difference between 2 groups | A: 95.23%P: 90.91% |
| Wu et al.[ | Retrospective study | 2018 | A: 73AP: 84P: 237 | A: 34.85±12.24AP: 33.71±11.96P: 35.80±13.11 | A: 14.86±13.01AP: 12.77±11.57P: 12.56±15.43 | Thoracic | N/A | N/A | preop: RFP/INH/EMB/PYZ for at least 2 weekspostop: RFP/INH/PYZ/EMB for at least 18 mo | A: 36.77±2.53AP: 37.30±3.29P: 37.09±3.12 | ASIA, VAS, ODI, ESR: improved in all 3 groups | A: 100%AP: 100%P: 100% |
| Huang et al.[ | Retrospective study | 2014 | AP: 7P: 16 | AP: 43.1P: 45.3 | N/A | AP: T: 2L: 0TL: 5P: T: 10L: 0TL: 6 | N/A | N/A | preop: INH/RFP/EMB/PYZ for 4 mo, followed by RFP/INH/PYZ for at least a further 9 mo | AP: 45.4P: 55.6 | ODI, ESR, CRP: improved | AP: 100%P: 100% |
| Liu et al.[ | Retrospective case-control | 2016 | AP: 16P: 18 | AP: 69.6±4.2P: 69.9±4.6 | 6 mo (average) | Thoracic | AP: 1.94P: 1.94 | N/A | preop: RFP/INH/EMB/PYZ for 14-21 days (mean, 15.7±1.9 days) postop: RFP/INH/PYZ/EMB for 12-18 mo | AP: 41.6±4.4P: 40.6±3.6 (mean follow-up time: 40.9±4.0) | Frankel scale, ERS, VAS: improved but no statistically significant difference between 2 groups | N/A |
A, anterior approach; P, posterior approach; AP, anterior combined with posterior approach; T, thoracic; TL, thoracolumbar; L, lumbar; LS, lumbosacral; preop, preoperative; postop, postoperative; INH: isoniazid; RFP: rifampicin; EMB: ethambutol; PYZ: pyrizinamide; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ODI: Oswestry Disability Index; VAS: visual analogue scale; ASIA: American Spinal Injury Association; N/A: not available.
Operative time and blood loss of different procedures for thoracic and lumbar spinal tuberculosis.
| Authors | Year | Operative time(A) (minutes) | Operative time(AP) (minutes) | Operative time(P) (minutes) | Blood loss(A) (mL) | Blood loss(AP) (mL) | Blood loss(P) (mL) |
|---|---|---|---|---|---|---|---|
| Qureshi et al.[ | 2013 | 125 | 344 | N/A | 1254 | 2213 | N/A |
| He et al.[ | 2012 | 190 | 497 | N/A | 410 | 980 | N/A |
| El-Sharkawi and Said[ | 2012 | N/A | 262 | 156 | N/A | 900 | 794 |
| Zhang et al.[ | 2012 | N/A | 445.6 | 349.4 | N/A | 1159.4 | 632.5 |
| Wang et al.[ | 2014 | N/A | 231.4 | 160 | N/A | 1023.8 | 760 |
| Li et al.[ | 2013 | 281.3 | 382.0 | 294.1 | 620.0 | 1002.0 | 1130.6 |
| Zhang et al.[ | 2017 | 270.7 | 349.7 | 349.7 | 649.0 | 840.0 | 409.5 |
| Huang et al.[ | 2017 | 200.1 | N/A | 236.0 | 671.6 | N/A | 732.3 |
| Cui et al.[ | 2016 | 210 | N/A | 240 | 450 | N/A | 560 |
| Hassan et al.[ | 2016 | 165 | N/A | 188.18 | 580.00 | N/A | 822.73 |
| Assaghir et al.[ | 2016 | 167.3 | N/A | 153.1 | 1015.2 | N/A | 986.6 |
| Wang et al.[ | 2017 | 256.6 | 388.2 | 170.6 | 798.7 | 1167.9 | 625.0 |
| Liu et al.[ | 2016 | N/A | 335.7 | 257.5 | N/A | 1048.6 | 769.6 |
| Omran et al.[ | 2017 | 190 | N/A | 165 | 700 | N/A | 950 |
| Xu et al.[ | 2015 | N/A | 276 .9 | 193.8 | N/A | 1187.5 | 804.7 |
| Shi et al.[ | 2014 | 175.8 | 318.5 | 143.8 | 1227.1 | 1889.7 | 467.7 |
| Lin et al.[ | 2015 | 196 | N/A | 142 | 1150 | N/A | 1142 |
| Wu et al.[ | 2018 | 315.44 | 424.62 | 270.79 | 706.16 | 1080.95 | 644.35 |
| Huang et al.[ | 2014 | N/A | N/A | N/A | N/A | N/A | N/A |
| Liu et al.[ | 2016 | N/A | 274.4 | 166.9 | N/A | 1075.6 | 776.9 |
A, anterior approach; P, posterior approach; AP, anterior combined with posterior approach; N/A, not available.
Preoperative kyphosis angle and correction of kyphosis angle in different procedures for thoracic and lumbar spinal tuberculosis.
| Author | Year | Preop KA (A) (degrees) | Preop KA (AP) (degrees) | Preop KA (P) (degrees) | Correction of KA (A) (degrees, %) | Correction of KA (AP) (degrees, %) | Correction of KA (P) (degrees, %) |
|---|---|---|---|---|---|---|---|
| Lee et al.[ | 2006 | 21.20 | N/A | 18.91 | 4.9 (22.9%) | N/A | 5.2 (27.3%) |
| Ma et al.[ | 2012 | 22.1 | N/A | 7.4 | 11.5 (52.0%) | N/A | 12.6 (170.3%) |
| Qureshi et al.[ | 2013 | 26.41 | N/A | 51.05 | 7.5 (28.5%) | N/A | 28.7 (56.3%) |
| El-Sharkawi and Said[ | 2012 | N/A | 21.7 | 23.7 | N/A | 18.3 (84.3%) | 19.9 (84.0%) |
| Zhang et al.[ | 2012 | N/A | 33.1 | 31.9 | N/A | 9.4 (28.4%) | 8.8 (27.8%) |
| Wang et al.[ | 2014 | N/A | 36.27 | 5.29 | N/A | 30.98 (85.45) | 24.11 (67.6%) |
| Li et al.[ | 2013 | 41.70 | 37.35 | 40.75 | 32.8 (77.4%) | 27.0 (74.7%) | 26.7 (69.9%) |
| Zhang et al.[ | 2017 | 22.9 | 23.9 | 28.5 | 52% | 69% | 74% |
| Huang et al.[ | 2017 | 12.2 | N/A | 4.6 | N/A | N/A | N/A |
| Cui et al.[ | 2016 | 32.1 | N/A | 33.8 | 10.2 (31.8%) | N/A | 12.6 (37.3%) |
| Hassan et al.[ | 2016 | 30.45 | N/A | 30.91 | 22.25 (73.1%) | N/A | 26.41 (85.44%) |
| Assaghir et al.[ | 2016 | 36.6 | N/A | 38.5 | 79.2% | N/A | 69.9% |
| Wang et al.[ | 2017 | 27.3 | 29.3 | 28.4 | 45.0% | 73.1% | 72.5% |
| Omran et al.[ | 2017 | 49 | N/A | 50 | 60.9% | N/A | 80% |
| Xu et al.[ | 2015 | N/A | 18.8 | 17.9 | N/A | 16.3 (86.7%) | 15.4 (89.5%) |
| Shi et al.[ | 2014 | N/A | N/A | N/A | N/A | N/A | N/A |
| Lin et al.[ | 2015 | 36.5 | N/A | 34.5 | 30.9% | N/A | 68.5% |
| Wu et al.[ | 2018 | 18.01 | 19.33 | 21.54 | N/A | N/A | N/A |
| Huang et al.[ | 2014 | N/A | 34.57 | 19.69 | N/A | 14.28 (41.31%) | 11.63 (59.07%) |
| Liu et al.[ | 2016 | N/A | 43.4 | 41.9 | N/A | 24.9 (57.37%) | 25.1 (59.90%) |
Preop, preoperative; KA, kyphosis angle; A, anterior approach; P, posterior approach; AP, anterior combined with posterior approach; N/A, not available.
Surgical complications of different procedures for thoracic and lumbar spinal tuberculosis.
| Complication | References | Anterior, n (%) | Anterior + posterior, n (%) | Posterior, n (%) |
|---|---|---|---|---|
|
| ||||
| Pleural effusion | 11, 18, 32, 54 | 4/29 (13.79%) | 3/71 (4.23%) | N/A |
| Pneumonia | 11,17, 33 | 1/7 (14.29%) | 3/32 (9.38%) | N/A |
| Pneumothorax | 17, 30, 34, 48 | 17/208 (8.17%) | 17/135 (12.59%) | 1/36 (2.78%) |
| Hemopneumothorax | 17 | N/A | 4/16 (25.00%) | N/A |
| Intercostal nerve injury | 29, 48 | N/A | N/A | 7/286 (2.44%) |
| Pleural injury | 48 | N/A | 3/84 (3.57%) | N/A |
| Lung parenchymal injury | 29 | 2/43 (4.65%) | N/A | N/A |
| Total | 25/294 (8.50%) | 30/338 (8.88%) | 8/322 (2.48%) | |
|
| ||||
| Loosening or pull-out of instrumentation | 11, 13, 20, 26, 30 | 8/192 (4.17%) | 1/83 (1.20%) | 3/120 (2.5%) |
| Cage subsidence | 32 | N/A | N/A | 3/22 (13.64%) |
| Unspecific | 14 | 6/57 (10.53%) | N/A | N/A |
| Total | 14/249 (5.62%) | 1/83 (1.20%) | 4/155 (2.58%) | |
|
| ||||
| Implant failure | 14, 16, 26 | 6/57 (12.28%) | 1/25 (4.00%) | 1/18 (5.56%) |
| Deformity | 14 | 1/57 (12.28%) | N/A | N/A |
| Total | 7/57 (12.28%) | 1/25 (4.00%) | 1/18 (5.56%) | |
| Recurrence | 30 | 2/57 (3.51%) | 2/65 (3.08%) | N/A |
|
| ||||
| Anti-TB drug-induced liver dysfunction | 33 | N/A | 1/16 (6.25%) | N/A |
| ARDS | 32 | 1/22 (4.54%) | N/A | N/A |
| Chest and back pain | 34 | 8/78 (10.26%) | 7/54 (12.96%) | 2/16 (12.50%) |
| CSF leakage | 17, 30, 48 | 2/57 (3.51%) | 2/65 (3.08%) | 9/299 (3.01%) |
| Donor site problem | 16, 31, 48 | 4/73 (5.48%) | 14/145 (9.66%) | 2/269 (0.74%) |
| Dural tear | 16, 27 | N/A | N/A | 3/65 (4.62%) |
| DVT | 16, 29 | 1/43 (2.33%) | 1/25 (4.00%) | N/A |
| Fistula | 33, 54 | N/A | 2/32 (6.25%) | N/A |
| Intercostal neuralgia | 18, 30, 32, 48, 54 | 2/95 (2.11%) | 5/84 (5.95%) | 4/163 (2.45%) |
| Intraoperative excessive bleeding | 32 | N/A | N/A | 1/23 (4.35%) |
| Local abscess | N/A | 1/16 (6.25%) | N/A | |
| Nerve root injury | 27 | N/A | N/A | 1/33 (3.03%) |
| Neural effusion | 30 | 2/57 (3.51%) | N/A | N/A |
| Nonunion | 27 | N/A | N/A | 1/33 (3.03%) |
| Paralytic ileus | 16, 31 | N/A | 2/61 (3.28%) | N/A |
| PE | 11 | N/A | N/A | 1/10 (10.00%) |
| Persistent injury | 29 | N/A | N/A | 3/49 (6.12%) |
| Postoperative paralysis | 27 | N/A | N/A | 1/33 (3.03%) |
| Pressure ulcer | 48 | N/A | 1/84 (1.19%) | N/A |
| Pseudarthrosis | 20, 26 | 1/39 (2.56%) | N/A | 1/42 (2.38%) |
| Psoas abscess | 33 | N/A | N/A | 1/17 (5.88%) |
| Residual neurological defects | 29 | 1/43 (2.33%) | N/A | 2/49 (4.08%) |
| Sinus formation | 12, 13, 18, 20, 30, 34 | 6/226 (2.65%) | 8/192 (4.17%) | 5/187 (2.67%) |
| Superficial infection | 29, 30, 32, 33, 34 | 9/200 (4.50%) | 18/135 (13.33%) | 5/150 (3.33%) |
| Urinary infection | 48 | N/A | 3/84 (3.57%) | N/A |
| Vascular injury | 20, 30, 32 | 2/57 (3.51%) | 3/65 (4.62%) | 3/80 (3.75%) |
| Water–electrolyte imbalance | 30, 48 | 7/130 (5.38%) | 11/149 (7.38%) | 2/62 (3.23%) |
| Wound dehiscence | 11, 16, 18 | 1/74 (1.35%) | 2/80 (2.50%) | 5/125 (4.00%) |
| Wound infection | 31, 34, 54 | 11/78 (14.10%) | 11/106 (10.38%) | 2/62 (3.23%) |
| Total | 103/1879 (5.48%)* | 126/1904 (6.62%)* | 67/2262 (2.96%) | |
Anti-TB, anti-tuberculous; ARDS, acute respiratory distress syndrome; CSF, cerebrospinal fluid; DVT, deep vein thrombosis; PE, pulmonary embolism; N/A, not available.
*P < 0.05, the incidence of overall surgical complication was significantly different between the anterior and anterior + posterior procedures.
Figure 2.Comparison of complications depending on the anterior, anterior combined with posterior, or posterior approach. *Statistical difference in transthoracic complications between anterior and posterior approach and between posterior and anterior combined with posterior approach (P < 0.05).